Outpatient albumin infusions reduce hospitalizations and improve outcomes in decompensated cirrhosis: A real‐world cohort study
JGH Open · 2023-08 · 7 (8) · 537-544
DOI: 10.1002/jgh3.12944 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift JGH Open, online erschienen am 27.07.2023. Verfasst von Nicholas Hannah und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology Royal Melbourne Hospital Melbourne Victoria Australia. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background and Aim Long‐term human albumin (HA) infusions improve survival in cirrhotic patients with diuretic resistant ascites. We aimed to determine whether there is a significant benefit in a more unwell real‐world cohort.
Methods
This is a single‐center retrospective cohort study. Patients received outpatient HA between April 2017 and June 2021. Inclusion criteria were age ≥18 years, cirrhosis with ascites, and received at least 1 month of HA. Patients with significant comorbidities and ongoing alcohol use were not excluded. Outcomes assessed were transjugular intrahepatic portosystemic shunt (TIPS)/transplant‐free survival (TTFS), and biochemical and prognostic outcomes.
Results
Twenty‐four patients were included. Median age was 59.5 years. Seven were female (29.2%). Etiology included were alcohol (50%), non‐alcoholic steatohepatitis (16.7%), and viral/alcohol (12.5%). Median model for end‐stage liver disease‐sodium (MELD‐Na) was 18.5, with Child–Pugh scores (CPS) A (4.2%), B (50%), and C (45.8%). Improvements in serum sodium ( P = 0.014), albumin ( P = 0.003), and CPS ( P = 0.017) were observed. Reduction in hospitalizations ( P = 0.001), particularly portal hypertensive related admissions was observed (relative risk 0.39; 95% confidence interval [CI] 0.21–0.69, P = 0.003), needed to treat 2.09 (95% CI 1.25–3.67). There was a reduction in total paracentesis requirements ( P = 0.005). On multivariate analysis, type 2 diabetes mellitus significantly increased risk of TIPS/transplant/death (hazard ratio 6.16; 95% CI 1.23–30.84, P = 0.027). Median TTFS improved in patients with a change in MELD‐Na ≤1 at 1 month: 29.4 months versus 7.7 months ( P = 0.011).
Conclusion
Outpatient HA infusions decrease portal hypertensive related hospital admissions, improve serum sodium, albumin levels, and CPS. Type 2 diabetes mellitus and change in MELD‐Na score help discriminate those likely to benefit most.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology Royal Melbourne Hospital Melbourne Victoria Australia.
- Melbourne Medical School, Faculty of Medicine, Dentistry and Health Sciences University of Melbourne Melbourne Victoria Australia.
- Department of Gastroenterology Northern Health Melbourne Victoria Australia.
- Department of Gastroenterology Alfred Health Melbourne Victoria Australia.
- Monash Medical School, Faculty of Medicine, Nursing and Health Sciences Melbourne Victoria Australia.
ORCID-Profile: Nicholas Hannah, Ashwin Patwardhan
Zitieren
APA
Hannah, N., Tjandra, D., Patwardhan, A., Rutland, K., Halliday, J., & Sood, S. (2023). Outpatient albumin infusions reduce hospitalizations and improve outcomes in decompensated cirrhosis: A real‐world cohort study. JGH Open, 7(8), 537-544. https://doi.org/10.1002/jgh3.12944
Vancouver
Hannah N, Tjandra D, Patwardhan A, Rutland K, Halliday J, Sood S. Outpatient albumin infusions reduce hospitalizations and improve outcomes in decompensated cirrhosis: A real‐world cohort study. JGH Open. 2023;7(8):537-544. doi:10.1002/jgh3.12944
BibTeX
@article{Hannah2023,
author = {Hannah, Nicholas and Tjandra, Douglas and Patwardhan, Ashwin and Rutland, Kelsey and Halliday, John and Sood, Siddharth},
title = {Outpatient albumin infusions reduce hospitalizations and improve outcomes in decompensated cirrhosis: A real‐world cohort study},
journal = {JGH Open},
year = {2023},
volume = {7},
number = {8},
pages = {537--544},
doi = {10.1002/jgh3.12944}
}
EUVIMED